MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvement

Clinical Immunology

Volumn 120, Issue 3, 2006, Pages 319-325

  O'Connor, Kevin A ^a   Abbott, Kathy A ^a   Sabin, Brad ^b   Kuroda, Maxine ^a   Pachman, Lauren M ^a,b,c  

^a CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Interferon; Juvenile dermatomyositis; Muscle; MxA; PBMC

Indexed keywords

GAMMA GLOBIN; HYDROXYCHLOROQUINE; MESSENGER RNA; METHOTREXATE; METHYLPREDNISOLONE; MYXOVIRUS RESISTANCE PROTEIN A; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATOMYOSITIS; DISEASE ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUSCLE DISEASE; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCORING SYSTEM; SKIN DEFECT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; CHILD; CREATINE KINASE; DERMATOMYOSITIS; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GTP-BINDING PROTEINS; HUMANS; L-LACTATE DEHYDROGENASE; MALE; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE, SKELETAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN;

EID: 33746797290     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.05.011     Document Type: Article

References (36)

1. Mendez E.P., Lipton R., Ramsey-Goldman R., Roettcher P., et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 49 3 (2003) 300-305
2. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292 7 (1975) 344-347
3. Bohan A., and Peter J.B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292 8 (1975) 403-407
4. Bode R.K., Klein-Gitelman M.S., Miller M.L., Lechman T.S., et al. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 49 1 (2003) 7-15
5. Smith R.L., Sundberg J., Shamiyah E., Dyer A., et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J. Rheumatol. 31 8 (2004) 1644-1649
6. O'Gorman M.R., Bianchi L., Zaas D., Corrochano V., et al. Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin. Diagn. Lab. Immunol. 7 4 (2000) 693-697
7. Tezak Z., Hoffman E.P., Lutz J.L., Fedczyna T.O., et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J. Immunol. 168 8 (2002) 4154-4163
8. Zhou X., Dimachkie M.M., Xiong M., Tan F.K., et al. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med. Sci. Monit. 10 7 (2004) BR191-BR197
9. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57 5 (2005) 664-678
10. Files J.G., Gray J.L., Do L.T., Foley W.P., et al. A novel sensitive and selective bioassay for human type I interferons. J. Interferon Cytokine Res. 18 12 (1998) 1019-1024
11. Pungor Jr. E., Files J.G., Gabe J.D., Do L.T., et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J. Interferon Cytokine Res. 18 12 (1998) 1025-1030
12. Roers A., Hochkeppel H.K., Horisberger M.A., Hovanessian A., et al. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J. Infect. Dis. 169 4 (1994) 807-813
13. Bertolotto A., Gilli F., Sala A., Audano L., et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 1-2 (2001) 141-152
14. von Wussow P., Jakschies D., Hochkeppel H.K., Fibich C., et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur. J. Immunol. 20 9 (1990) 2015-2019
15. Antonelli G., Simeoni E., Turriziani O., Tesoro R., et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J. Interferon Cytokine Res. 19 3 (1999) 243-251
16. Pachman L.M., Abbott K., Sincacore J.M., Amoruso L., et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J. Pediatr. 148 2 (2006) 247-253
17. Bave U., Nordmark G., Lovgren T., Ronnelid J., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 52 4 (2005) 1185-1195
18. Crow M.K., Kirou K.A., and Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36 8 (2003) 481-490
19. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 52 5 (2005) 1534-1544
20. Pascual V., Banchereau J., and Palucka A.K. The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol. 15 5 (2003) 548-556
21. Uzel G., Conboy C.M., Giczewski D., Abbott K., et al. Decreased ICAM-1+ memory suppressor T cells in untreated juvenile dermatomyositis peripheral blood. Clin. Invest. Med. 27 (2004) (Suppl.)
22. McDouall R.M., Dunn M.J., and Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J. Neurol. Sci. 99 2-3 (1990) 199-217
23. Mizuno K., Yachie A., Nagaoki S., Wada H., et al. Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome. Clin. Exp. Immunol. 137 1 (2004) 187-194
24. Li C.K., Varsani H., Holton J.L., Gao B., et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J. Rheumatol. 31 3 (2004) 605-609
25. Massa M., Costouros N., Mazzoli F., De Benedetti F., et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 46 11 (2002) 3015-3025
26. Pachman L.M., Lipton R., Ramsey-Goldman R., Shamiyeh E., et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 53 2 (2005) 166-172
27. Tough D.F., Borrow P., and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272 5270 (1996) 1947-1950
28. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10 5 (1998) 383-390
29. Reiter Z. Interferon-a major regulator of natural killer cell-mediated cytotoxicity. J. Interf. Res. 13 4 (1993) 247-257
30. Keir M.E., Stoddart C.A., Linquist-Stepps V., Moreno M.E., et al. IFN-alpha secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J. Immunol. 168 1 (2002) 325-331
31. Ronnblom L., Eloranta M.L., and Alm G.V. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 36 8 (2003) 463-472
32. Dietrich L.L., Bridges A.J., and Albertini M.R. Dermatomyositis after interferon alpha treatment. Med. Oncol. 17 1 (2000) 64-69
33. Kirou K.A., Lee C., George S., Louca K., et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 5 (2005) 1491-1503
34. Shodell M., Shah K., and Siegal F.P. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 12 3 (2003) 222-230
35. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 5421 (1999) 1835-1837
36. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., et al. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159 1 (2001) 237-243